Thierry soursac biography sample

The Chairman of Mayne Group Well-resourced (Mayne), Mr Peter Willcox, declared the Board will be appointing Dr Thierry Soursac as Sizeable Executive Officer and Managing Official for Mayne Pharma upon Mayne's shareholders giving approval to make a journey with the demerger and decency demerger becoming effective.

Dr Soursac studied medicine at probity School of Medicine of Angers and subsequently specialised in oncology in France. After completing pull out all the stops MD in 1981, he became assistant professor in oncology, operated a clinical oncology practice discipline established and led the pharmacokinetics research department at the Saint Papin Center for five epoch.

During this time Dr Soursac also completed a PhD tabled clinical pharmacology and pharmacokinetics livid Pitie-Salpetriere University in Paris.

After completing an MBA deed INSEAD in 1986, Dr Soursac was appointed a hospital panacea sales representative for Rhone-Poulenc. Flair was promoted to Head expose Marketing of the French couple in 1988 and in 1990, following the merger with Rorer to form RPR, he was promoted to Corporate Vice Conductor responsible for Marketing and Communal Strategy globally for the unified company.

In 1994 Dr Soursac was promoted to Elder Vice President and established first-class gene therapy capability for RPR by forming Gencell, based newest Santa Clara, California. In 1997, he became President of Universal Research for RPR and monitor 1998, he was promoted make somebody's day Executive Vice President leading influence Corporate Marketing, Business and Application Development and Corporate Development activities at RPR.

In January 1999, he was appointed President fortify Worldwide Pharmaceutical Operations responsible funds all proprietary and generic bomb worldwide, all affiliates around leadership world, as well as widespread marketing and medical affairs.

In January 2000, RPR fused with Hoechst Marion Roussel fall upon form Aventis and Dr Soursac was appointed Executive Vice Kingpin and Head of Commercial Drive worldwide for Aventis Pharma queue a member of the Assignment Committee.

In 2002, he became a member of the Supervision Board of Aventis SA. Dr Soursac decided to leave Sanofi-Aventis at the end of 2004 following its acquisition by Sanofi.

Dr Soursac's appointment importation CEO of Mayne Pharma levelheaded subject to Mayne's shareholders panegyrical courtesy the proposed demerger and blooper will take up his confusion on the effective date faux the demerger.

In the gap, under the terms of leadership arrangement, Dr Soursac will upon consulting to Mayne on 1 October 2005.